Hirudins: antithrombin anticoagulants
- PMID: 1482812
- DOI: 10.1177/106002809202601211
Hirudins: antithrombin anticoagulants
Abstract
Objective: To review the chemistry, pharmacology, available clinical data, and adverse effects of the hirudin anticoagulants.
Data sources: A MEDLINE search and a review of recent scientific abstracts was conducted to identify pertinent literature.
Study selection: Focus was placed on studies conducted in humans. Because hirudin is still an investigational agent, however, relevant animal data, particularly pharmacokinetic studies and studies of preclinical efficacy, were also selected.
Data extraction: Data from both human and animal studies were evaluated; emphasis was placed on human trials.
Data synthesis: Hirudin has demonstrated potent anticoagulant effects. Although hirudin could have a significant impact on the therapeutic management of patients requiring anticoagulant therapy, only a limited number of human studies have been published to date. Trials comparing hirudin and heparin in specific patient populations are still ongoing.
Conclusions: Although still in clinical trials, hirudin is a unique agent that may represent a breakthrough in anticoagulant therapy. The specific role that this agent will play in the management of patients has yet to be determined.
Similar articles
-
Hirudin as alternative anticoagulant--a historical review.Semin Thromb Hemost. 2002 Oct;28(5):405-14. doi: 10.1055/s-2002-35292. Semin Thromb Hemost. 2002. PMID: 12420235 Review.
-
Hirudin: the famous anticoagulant agent.Adv Exp Med Biol. 1993;340:191-211. doi: 10.1007/978-1-4899-2418-6_18. Adv Exp Med Biol. 1993. PMID: 8154337 Review. No abstract available.
-
The anticoagulant and antithrombotic properties of hirudins.Thromb Haemost. 1990 Nov 30;64(3):344-8. Thromb Haemost. 1990. PMID: 2096484 Review. No abstract available.
-
Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.Thromb Haemost. 1999 Feb;81(2):250-5. Thromb Haemost. 1999. PMID: 10064001
-
Lepirudin for heparin-induced thrombocytopenia.Med Lett Drugs Ther. 1998 Sep 25;40(1036):94-5. Med Lett Drugs Ther. 1998. PMID: 9774965 No abstract available.
Cited by
-
New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin.Br J Pharmacol. 2005 Apr;144(8):1017-28. doi: 10.1038/sj.bjp.0706153. Br J Pharmacol. 2005. PMID: 15711585 Free PMC article. Review.
-
Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin.Drugs Aging. 1996 Mar;8(3):171-82. doi: 10.2165/00002512-199608030-00003. Drugs Aging. 1996. PMID: 8720743 Review.
-
Hirudin and excess bleeding. Implications for future use.Drug Saf. 1995 Apr;12(4):234-9. doi: 10.2165/00002018-199512040-00002. Drug Saf. 1995. PMID: 7646821 Review. No abstract available.
-
Novel antithrombotic drugs in development.Drugs. 1995 Jun;49(6):856-84. doi: 10.2165/00003495-199549060-00002. Drugs. 1995. PMID: 7641602 Review.
-
Pharmacokinetic optimisation of the treatment of deep vein thrombosis.Clin Pharmacokinet. 1997 Feb;32(2):145-72. doi: 10.2165/00003088-199732020-00005. Clin Pharmacokinet. 1997. PMID: 9068929 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources